Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 2026
Source Summary
TOKYO--(BUSINESS WIRE)--Meiji Seika Pharma: Lancet Microbe's ESCMID 2026 coverage highlights global Phase III Integral-2 results for novel β-lactamase inhibitor nacubactam.
Advertisement